Expresión de O6 -metilguanina-ADN-metiltransferasa (MGMT) en pacientes chilenos con glioblastoma multiforme
Author
dc.contributor.author
Jiménez Fernández, Daniel Andrés
Author
dc.contributor.author
Matamala, José Manuel
Author
dc.contributor.author
Chiti, Alessandra
Author
dc.contributor.author
Vergara, Carmen
Author
dc.contributor.author
Tissera, Claudia
Author
dc.contributor.author
Melo, Rómulo
Author
dc.contributor.author
Cartier Rovirosa, Luis
Admission date
dc.date.accessioned
2018-10-10T13:37:25Z
Available date
dc.date.available
2018-10-10T13:37:25Z
Publication date
dc.date.issued
2018
Cita de ítem
dc.identifier.citation
Rev Med Chile 2018; 146: 7-14
es_ES
Identifier
dc.identifier.issn
0034-9887
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/152063
Abstract
dc.description.abstract
Background: Patients with Glioblastoma multiforme (GBM) have a five years survival of less than 5%, but the response to chemotherapy with alkylating agents can vary depending on the methylation status of O-6-methylguanine-DNA-methyltransferase (MGMT). Genetic testing has limitations for routine use, while immunohistochemistry (IHC) offers a fast and affordable technique but with heterogeneous results in the literature. Aim: To evaluate MGMT expression by IHC in tumor tissue of Chilean patients with GBM. Material and Methods: Tumor samples of 29 patients with a pathological diagnosis of GBM were studied. We performed IHC staining and manual analysis of positive and negative cells for MGMT expression. A cut-off of at least 10% of cells expressing MGMT was used. Demographic and clinical features of patients were obtained from clinical records. Results: The median number of cells counted per case was 692 (interquartile range [IQR] 492-928). Fifteen cases (52%) were positive for MGMT expression. Median overall survival was 5.3 months (IQR 3.4-12-8). The effect of MGMT expression on the therapeutic response was not studied since only 3 patients received chemotherapy. Conclusions: Our results are similar to international reports, but we were not able to determine the association between MGMT expression and therapeutic response.